Expression and subcellular localization of the bromodomain-containing protein 7 is a prognostic biomarker in breast cancer.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Breast Neoplasms
/ genetics
Chromosomal Proteins, Non-Histone
/ genetics
CpG Islands
DNA Methylation
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Middle Aged
Prognosis
Promoter Regions, Genetic
Retrospective Studies
Subcellular Fractions
/ metabolism
Survival Rate
Tumor Cells, Cultured
Journal
Anti-cancer drugs
ISSN: 1473-5741
Titre abrégé: Anticancer Drugs
Pays: England
ID NLM: 9100823
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
14
1
2020
medline:
3
2
2021
entrez:
14
1
2020
Statut:
ppublish
Résumé
Bromodomain-containing protein 7 (BRD7) is a member of the bromodomain-containing protein family. Previous studies suggest that BRD7 is predominantly localized in the nucleus, wherein it functions as a transcriptional regulator. Several lines of evidence imply a tumour suppressor function for BRD7. However, the importance of BRD7 in the pathogenesis of breast cancer is not well understood. We have investigated the expression, CpG island methylation and subcellular localization of BRD7 in breast cancer cell lines and clinical cases and thereby assessed its prognostic significance by correlating with clinical-pathological features and time-dependent clinical outcomes. We show that nuclear exclusion of BRD7 occurs commonly in breast cancer and is strongly associated with cases expressing wild-type p53. Moreover, clinical outcomes are significantly less favourable in cases with nuclear exclusion or loss of expression than those in which there is nuclear expression of BRD7. Methylation of the CpG island of BRD7 increases in breast cancer relative to normal breast tissue, but there is not an obvious correlation between methylation and reduced expression or between methylation and clinical outcomes. Overall, our results suggest that nuclear exclusion, rather than transcriptional silencing, is a common mechanism by which the tumour suppressor function of wild-type p53 is inhibited in breast cancer, and show that BRD7 is a promising candidate biomarker in breast cancer.
Identifiants
pubmed: 31929348
doi: 10.1097/CAD.0000000000000897
pii: 00001813-202004000-00013
doi:
Substances chimiques
BRD7 protein, human
0
Biomarkers, Tumor
0
Chromosomal Proteins, Non-Histone
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
423-430Références
McGuire A, Brown JA, Malone C, McLaughlin R, Kerin MJ. Effects of age on the detection and management of breast cancer. Cancers (Basel). 2015; 7:908–929
Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sroczynski G, et al. Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests oncotypedx and adjuvant!online. BMC Cancer. 2017; 17:685
Cuppen E, van Ham M, Pepers B, Wieringa B, Hendriks W. Identification and molecular characterization of BP75, a novel bromodomain-containing protein. FEBS Lett. 1999; 459:291–298
Zhou M, Liu H, Xu X, Zhou H, Li X, Peng C, et al. Identification of nuclear localization signal that governs nuclear import of BRD7 and its essential roles in inhibiting cell cycle progression. J Cell Biochem. 2006; 98:920–930
Jeanmougin F, Wurtz JM, Le Douarin B, Chambon P, Losson R. The bromodomain revisited. Trends Biochem Sci. 1997; 22:151–153
Staal A, Enserink JM, Stein JL, Stein GS, van Wijnen AJ. Molecular characterization of celtix-1, a bromodomain protein interacting with the transcription factor interferon regulatory factor 2. J Cell Physiol. 2000; 185:269–279
Dyson MH, Rose S, Mahadevan LC. Acetyllysine-binding and function of bromodomain-containing proteins in chromatin. Front Biosci. 2001; 6:D853–D865
Peng C, Zhou J, Liu HY, Zhou M, Wang LL, Zhang QH, et al. The transcriptional regulation role of BRD7 by binding to acetylated histone through bromodomain. J Cell Biochem. 2006; 97:882–892
Kaeser MD, Aslanian A, Dong MQ, Yates JR III, Emerson BM. BRD7, a novel PBAF-specific SWI/SNF subunit, is required for target gene activation and repression in embryonic stem cells. J Biol Chem. 2008; 283:32254–32263
Peng C, Liang SP, Tan C, Lv HB, Huang H, Zhou M, et al. Researching a novel NPC-related candidate suppressor gene BRD7 by two-dimensional gel electrophoresis and MALDI-TOF-MS. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003; 35:816–822
Peng C, Liu HY, Zhou M, Zhang LM, Li XL, Shen SR, Li GY. BRD7 suppresses the growth of nasopharyngeal carcinoma cells (HNE1) through negatively regulating beta-catenin and ERK pathways. Mol Cell Biochem. 2007; 303:141–149
Drost J, Mantovani F, Tocco F, Elkon R, Comel A, Holstege H, et al. BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol. 2010; 12:380–389
Chiu YH, Lee JY, Cantley LC. BRD7, a tumor suppressor, interacts with p85α and regulates PI3K activity. Mol Cell. 2014; 54:193–202
Harte MT, O’Brien GJ, Ryan NM, Gorski JJ, Savage KI, Crawford NT, et al. BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res. 2010; 70:2538–2547
Kikuchi M, Okumura F, Tsukiyama T, Watanabe M, Miyajima N, Tanaka J, et al. TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. Biochim Biophys Acta. 2009; 1793:1828–1836
Wu WJ, Hu KS, Chen DL, Zeng ZL, Luo HY, Wang F, et al. Prognostic relevance of BRD7 expression in colorectal carcinoma. Eur J Clin Invest. 2013; 43:131–140
Hu K, Liao D, Wu W, Han AJ, Shi HJ, Wang F, et al. Targeting the anaphase-promoting complex/cyclosome (APC/C)- bromodomain containing 7 (BRD7) pathway for human osteosarcoma. Oncotarget. 2014; 5:3088–3100
Park YA, Lee JW, Kim HS, Lee YY, Kim TJ, Choi CH, et al. Tumor suppressive effects of bromodomain-containing protein 7 (BRD7) in epithelial ovarian carcinoma. Clin Cancer Res. 2014; 20:565–575
Niu W, Luo Y, Wang X, Zhou Y, Li H, Wang H, et al. BRD7 inhibits the warburg effect and tumor progression through inactivation of HIF1α/LDHA axis in breast cancer. Cell Death Dis. 2018; 9:519
Ma J, Niu W, Wang X, Zhou Y, Wang H, Liu F, et al. Bromodomain-containing protein 7 sensitizes breast cancer cells to paclitaxel by activating bcl2-antagonist/killer protein. Oncol Rep. 2019; 41:1487–1496
Penkert J, Schlegelberger B, Steinemann D, Gadzicki D. No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways. Fam Cancer. 2012; 11:601–606
Pern F, Bogdanova N, Schürmann P, Lin M, Ay A, Länger F, et al. Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of german patients with triple-negative breast cancer. PLoS One. 2012; 7:e47993
Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, et al. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol. 2013; 133:1278–1285
Chen CL, Wang Y, Pan QZ, Tang Y, Wang QJ, Pan K, et al. Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma. Oncotarget. 2016; 7:16248–16261
Xu K, Xiong W, Zhou M, Wang H, Yang J, Li X, et al. Integrating chip-sequencing and digital gene expression profiling to identify BRD7 downstream genes and construct their regulating network. Mol Cell Biochem. 2016; 411:57–71